Key result
A novel radioimmunoassay using digoxin 3'-hemisuccinate-BSA conjugate antiserum demonstrated high specificity for unmetabolized digoxin, measuring a mean concentration of 0.68 ng/ml in patient samples compared to 0.79-0.80 ng/ml with commercial antibodies.
Why the study?
Does a novel radioimmunoassay using digoxin 3'-hemisuccinate-BSA conjugate antiserum accurately measure serum digoxin in digitalized patients compared to commercial assays?
Does a novel radioimmunoassay using digoxin 3'-hemisuccinate-BSA conjugate antiserum accurately measure serum digoxin in digitalized patients compared to commercial assays?
A novel radioimmunoassay for serum digoxin demonstrates sufficient precision for clinical use in digitalized patients.
Answers are grounded in this paper and cite their sources.
May enhance digoxin assay specificity in practice; leaves open whether lower readings affect dosing or outcomes.
There is an antiserum elicited by digoxin 3'-hemisuccinate-bovine serum albumin (BSA) conjugate possessing high specificity for digoxin. Our study focused on development of RIA using this novel antiserum for measurement of digoxin in serum from digitalized patients. The property of the new antiserum was investigated by RIA with digoxin 3'-hemisuccinyl-[3H]leucine. The separation of bound and free fractions was performed using a dextran-coated charcoal suspension. The new antiserum bound approximately 50% of digoxin 3'-hemisuccinyl-[3H]leucine with a final dilution of 1:30000. The intra- and inter-assay coefficients of variation were <9% in the range of 0.52-4.17 ng/ml. The mean digoxin concentration in serum samples (n=35) from digitalized patients was estimated to be 0.68 ng/ml, which was lower than its measurement of digoxin with the commercial antidigoxin BSA serum and monoclonal anti-digoxin. It is apparent that the RIA described here has sufficient precision. The RIA system was available for the measurement of digoxin in serum from digitalized patients.
No takes yet. Share an insight, caveat, or question.
Ikeda et al. (2002) studied Digitalized patients (n=35). Novel anti-digoxin antiserum (antibody A) vs. Commercial anti-digoxin BSA serum and monoclonal anti-digoxin was evaluated on Mean digoxin concentration (ng/ml). A novel radioimmunoassay using digoxin 3'-hemisuccinate-BSA conjugate antiserum demonstrated high specificity for unmetabolized digoxin, measuring a mean concentration of 0.68 ng/ml in patient samples compared to 0.79-0.80 ng/ml with commercial antibodies.
Synapse has enriched 10 related papers. Consider them for comparative context: